Format

Send to

Choose Destination

See 1 citation found by title matching your search:

Eur J Radiol. 2012 Nov;81(11):3624-30. doi: 10.1016/j.ejrad.2011.05.036. Epub 2011 Jun 29.

Feasibility of MRI-guided high intensity focused ultrasound treatment for adenomyosis.

Author information

1
State Key Laboratory of Ultrasound Engineering in Medicine, Department of Biomedical Engineering, Chongqing Medical University, Clinical Center of Tumor Therapy, 2nd Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China.

Abstract

PURPOSE:

To test the feasibility of MRI-guided high intensity focused ultrasound ablation for adenomyosis.

MATERIALS AND METHODS:

Patients with symptomatic adenomyosis were treated with MRI-guided high intensity focused ultrasound (MRIgHIFU). Under conscious sedation, MRIgHIFU was performed by a clinical MRI-compatible focused ultrasound tumour therapeutic system (JM15100, Haifu® Technology Co. Ltd., Chongqing, China) which is combined with a 1.5 T MRI system (Magnetom Symphony, Siemens Healthcare, Erlangen, Germany). MRI was used to calculate the volume of the uterus and lesion. Non-perfused volume of the targeted lesions was evaluated immediately after MRIgHIFU. Patient symptoms were assessed using symptom severity score (SSS) and uterine fibroids symptoms and quality of life questionnaire (UFS-QOL).

RESULTS:

Ten patients with mean age of 40.3±4 years with an average lesion size of 56.9±12.7 mm in diameter were treated. Non-perfused volume and the percentage of non-perfused volume obtained from contrast-enhanced T1 Magnetic resonance images immediately post-treatment were 66.6±49.4 cm3 and 62.5±21.6%, respectively. The mean SSS and UFS-QOL showed significant improvements of 25%, 16% and 25% at 3, 6 and 12 months follow up, respectively, to pre-treatment scores. No serious complications were observed.

CONCLUSION:

Based on the results from this study, MRIgHIFU treatment appears to be a safe and feasible modality to ablate adenomyosis lesion and alleviate its symptoms.

PMID:
21719223
DOI:
10.1016/j.ejrad.2011.05.036
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center